Skip to main content

Table 4 Satisfaction regarding IgRT at enrollment

From: Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort “Visages”

 

LQI Factor I

LQI Factor II

LQI Factor III

Hospital-based IVIg

81.2 ± 2.5

85.8 ± 2.3

82.3 ± 2.5

Home-based IVIg

72.8 ± 4.7

79.5 ± 4.1

86.9 ± 4.5

Home-based SCIg

85.6 ± 2.3

85.6 ± 1.9

91.5 ± 2.2

Hospital-based IVIg vs home based IVIg

[-2.3 to 19.0]

P = 0.12

[-2.8 to 15.5]

P = 0.17

[14.8 to 5.5

P = 0.37

Hospital-based IVIg vs home based SCIg

[-11.1 to 2.2]

P = 0.19

[-5.5 to 6.0]

P = 0.93

[-15.5 to -2.8]

P = 0.005

Home-based IVIg vs home based SCIg

[-23.3 to -2.3]

P = 0.02

[-15.1 to 2.9]

P = 0.18

[-14.6 to 5.4]

P = 0.37

  1. Results are expressed as mean ± standard error. Contrasts are derived from a mixed model with route, place and route by place interaction as fixed factor and center as random factor. Contrasts are provided as two-sided 95 % confidence interval and p value